Weigang Xiu

462 total citations
25 papers, 200 citations indexed

About

Weigang Xiu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Weigang Xiu has authored 25 papers receiving a total of 200 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in Weigang Xiu's work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Weigang Xiu is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Weigang Xiu collaborates with scholars based in China and Germany. Weigang Xiu's co-authors include Jingjing Luo, Man Zhang, Xin Xue, Pan Ma, Huamin Han, Youling Gong, Jia Cai, Juan Ma, Hua Tao and Chenghai Zhao and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Frontiers in Immunology.

In The Last Decade

Weigang Xiu

23 papers receiving 196 citations

Peers

Weigang Xiu
Changbo Sun China
Noah Rozich United States
Wei Huff United States
Jacob Stultz United States
Rasmus Peuliche Vogelsang Denmark
Anne Sibille Belgium
Rainer Christoph Miksch Germany
Busra Isik United States
Mei Xie China
Yoshinao Takano Japan
Changbo Sun China
Weigang Xiu
Citations per year, relative to Weigang Xiu Weigang Xiu (= 1×) peers Changbo Sun

Countries citing papers authored by Weigang Xiu

Since Specialization
Citations

This map shows the geographic impact of Weigang Xiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weigang Xiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weigang Xiu more than expected).

Fields of papers citing papers by Weigang Xiu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weigang Xiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weigang Xiu. The network helps show where Weigang Xiu may publish in the future.

Co-authorship network of co-authors of Weigang Xiu

This figure shows the co-authorship network connecting the top 25 collaborators of Weigang Xiu. A scholar is included among the top collaborators of Weigang Xiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weigang Xiu. Weigang Xiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xiu, Weigang, et al.. (2024). The role of cholesterol metabolism in lung cancer. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 32(10). 1613–1621. 4 indexed citations
2.
3.
Xiu, Weigang, Yuwen Zhou, He Du, et al.. (2023). A nomogram for the prediction of the survival of patients with advanced non‐small cell lung cancer and interstitial lung disease. Cancer Medicine. 12(10). 11375–11384. 3 indexed citations
4.
5.
Xiu, Weigang, et al.. (2023). Immune-related mechanisms and immunotherapy in extragonadal germ cell tumors. Frontiers in Immunology. 14. 1145788–1145788. 3 indexed citations
6.
Zhang, Yan, Lin Zhou, Youling Gong, et al.. (2023). Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). 9112–9112. 8 indexed citations
7.
8.
Su, Chao, Weigang Xiu, Weiya Wang, et al.. (2022). Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report. JTO Clinical and Research Reports. 3(6). 100343–100343. 9 indexed citations
9.
Zhou, Lin, Conghua Xie, Youling Gong, et al.. (2022). Efficacy and safety of low-dose radiotherapy (LDRT) concurrent atezolizumab plus chemotherapy as first-line therapy for ES-SCLC : Interim analysis of Phase II MATCH trial.. Journal of Clinical Oncology. 40(16_suppl). e20611–e20611. 3 indexed citations
10.
11.
Xiu, Weigang, Qianqian Zhang, Min Yu, Yin Huang, & Meijuan Huang. (2021). Case Report: Outcome of Osimertinib Treatment in Lung Adenocarcinoma Patients With Acquired KRAS Mutations. Frontiers in Oncology. 11. 630256–630256. 7 indexed citations
12.
Xiu, Weigang & Jingjing Luo. (2021). CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling. BMC Immunology. 22(1). 18–18. 25 indexed citations
13.
Sun, Yu, Yan Fu, Weigang Xiu, et al.. (2021). A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy. Frontiers in Oncology. 11. 788837–788837. 1 indexed citations
14.
15.
16.
17.
Sun, Yu, et al.. (2020). Overall survival benefit of continuing immune checkpoint inhibitors treatment post dissociated response in patients with advanced lung cancer. Journal of Cancer Research and Clinical Oncology. 146(11). 2979–2988. 8 indexed citations
18.
Sun, Yuling, et al.. (2020). Knowledge Difference of Tumor Nutrition Risk Among Thoracic Cancer Patients, Their Family Members, Physicians, and Nurses. Journal of Cancer Education. 37(3). 524–531. 3 indexed citations
19.
Ma, Juan, Jing Ge, Xin Xue, et al.. (2018). Targeting bladder cancer using activated T�cells armed with bispecific antibodies. Oncology Reports. 39(3). 1245–1252. 6 indexed citations
20.
Xiu, Weigang, Juan Ma, Ting Lei, & Man Zhang. (2018). AG490 reverses phenotypic alteration of dendritic cells by bladder cancer cells. Oncology Letters. 16(3). 2851–2856. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Changbo Sun Breakdown of academic impact, for papers by Noah Rozich Breakdown of academic impact, for papers by Wei Huff Breakdown of academic impact, for papers by Jacob Stultz Breakdown of academic impact, for papers by Rasmus Peuliche Vogelsang Breakdown of academic impact, for papers by Anne Sibille Breakdown of academic impact, for papers by Rainer Christoph Miksch Breakdown of academic impact, for papers by Busra Isik Breakdown of academic impact, for papers by Mei Xie Breakdown of academic impact, for papers by Yoshinao Takano
Rankless by CCL
2026